IFC – Industrial Farmacéutica Cantabria – takes on a new challenge with the opening of a subsidiary in Mexico as part of its strategy to intensify and boost its international presence, which already forms 65% of its turnover.

IFC Manging Director, Juan Matji, announced that “the opening of IFC Mexico is a true reflection of the entrepreneurial spirit of the company, which sees an opportunity in the Mexican market. We plan to contract 120 individuals over this year with the initial marketing of our brands: Heliocare, Endocare, Biretix and Neoretin”.

IFC closed the 2016 financial year with a turnover of 120 million euros, 65% of which was due to exports and international distribution from its two production centres in Madrid and Santander. The patented ingredients and scientific endorsements of its products make the laboratory the most prescribed in dermatology in Spain and it has set its sights on becoming a global leader.

Over the last 5 years, IFC has opened up markets in a total of 20 new countries including Russia, China, Japan or Qatar, as part of its bid to become a prestigious international laboratory in healthcare. The pharmaceutical company has 5 of its own subsidiaries in Italy (2003), Germany (2008), Portugal (2009) and Morocco (2015), a symbol of the enterprising spirit of the laboratory that already has over 25 years of history producing and innovating with its pharmaceutical, nutricosmetic and cosmeceutical products.